tradingkey.logo

Cibus Inc

CBUS
1.370USD
-0.075-5.19%
Close 11/04, 16:00ETQuotes delayed by 15 min
71.90MMarket Cap
LossP/E TTM

Cibus Inc

1.370
-0.075-5.19%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Cibus Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cibus Inc's Score

Industry at a Glance

Industry Ranking
142 / 210
Overall Ranking
345 / 4617
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
14.400
Target Price
+800.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Cibus Inc Highlights

StrengthsRisks
Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 2614.65% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.26M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.26M.
Overvalued
The company’s latest PE is -0.14, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 12.60M shares, decreasing 0.28% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 856.15K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.12.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.23, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 933.00K, representing a year-over-year increase of 11.34%, while its net profit experienced a year-over-year increase of 1.97%.

Score

Industry at a Glance

Previous score
5.23
Change
0

Financials

4.03

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.98

Operational Efficiency

2.57

Growth Potential

5.48

Shareholder Returns

7.11

Cibus Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 8.68, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -0.14, which is -43.02% below the recent high of -0.08 and -1541.43% above the recent low of -2.27.

Score

Industry at a Glance

Previous score
8.68
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 142/210
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 7.50, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Cibus Inc is 15.50, with a high of 25.00 and a low of 1.60.

Score

Industry at a Glance

Previous score
7.50
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts
Buy
Current Rating
14.400
Target Price
+896.54%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Cibus Inc
CBUS
4
Boston Scientific Corp
BSX
37
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 3.61, which is lower than the Healthcare Equipment & Supplies industry's average of 6.72. Sideways: Currently, the stock price is trading between the resistance level at 1.84 and the support level at 1.20, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.24
Change
-0.63

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.046
Neutral
RSI(14)
43.112
Neutral
STOCH(KDJ)(9,3,3)
20.756
Sell
ATR(14)
0.137
High Vlolatility
CCI(14)
-216.541
Oversold
Williams %R
90.000
Oversold
TRIX(12,20)
0.407
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
1.509
Sell
MA10
1.535
Sell
MA20
1.539
Sell
MA50
1.429
Sell
MA100
1.471
Sell
MA200
1.840
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.39. The latest institutional shareholding proportion is 23.97%, representing a quarter-over-quarter decrease of 60.29%. The largest institutional shareholder is The Vanguard, holding a total of 856.15K shares, representing 1.63% of shares outstanding, with 46.47% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Riggs (Rory B)
14.63M
+396.82%
Fidelity Management & Research Company LLC
7.17M
+55.97%
JPL Investments SA
1.67M
-0.73%
Vantage Consulting Group, Inc.
1.14M
--
Gratia Capital, LLC
857.00K
--
The Vanguard Group, Inc.
Star Investors
856.15K
-4.03%
BlackRock Institutional Trust Company, N.A.
456.21K
-55.78%
Beetham (Peter Ronald)
382.44K
--
Gocal (Gregory Francis William)
374.84K
+19.06%
Geode Capital Management, L.L.C.
257.74K
-45.58%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.28, which is lower than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 1.63. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
2.28
Change
0
Beta vs S&P 500 index
1.62
VaR
+9.83%
240-Day Maximum Drawdown
+74.28%
240-Day Volatility
+116.90%

Return

Best Daily Return
60 days
+11.56%
120 days
+21.30%
5 years
+90.25%
Worst Daily Return
60 days
-9.69%
120 days
-34.32%
5 years
-34.32%
Sharpe Ratio
60 days
+0.25
120 days
-0.55
5 years
-0.49

Risk Assessment

Maximum Drawdown
240 days
+74.28%
3 years
+96.03%
5 years
+99.79%
Return-to-Drawdown Ratio
240 days
-0.92
3 years
-0.29
5 years
-0.20
Skewness
240 days
-0.22
3 years
+2.23
5 years
+1.87

Volatility

Realised Volatility
240 days
+116.90%
5 years
+128.56%
Standardised True Range
240 days
+15.53%
5 years
+381.85%
Downside Risk-Adjusted Return
120 days
-71.27%
240 days
-71.27%
Maximum Daily Upside Volatility
60 days
+83.36%
Maximum Daily Downside Volatility
60 days
+53.01%

Liquidity

Average Turnover Rate
60 days
+1.37%
120 days
+0.95%
5 years
--
Turnover Deviation
20 days
-11.75%
60 days
+103.34%
120 days
+41.79%

Peer Comparison

Healthcare Equipment & Supplies
Cibus Inc
Cibus Inc
CBUS
5.36 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
Artivion Inc
AORT
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI